SCHEMBL769441

SCHEMBL769441

CC(C)N(C(C)C)P(=O)(CCC#N)N(C(C)C)C(C)C

nearest known ligand 0.33

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.33
NLRP3 Q96P20 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8919030 0.79 TSHR (0.31) TSHRNLRP3
SCHEMBL18048378 0.69 TSHR (0.30) TSHRNLRP3
SCHEMBL3501857 0.69 TSHR (0.30) TSHRNLRP3
SCHEMBL31402658 0.69 TSHR (0.30) TSHRNLRP3
SCHEMBL1472140 0.67
SCHEMBL3565320 0.67
SCHEMBL1976528 0.67
SCHEMBL29028507 0.67 THRB (0.30)
SCHEMBL19445479 0.67
SCHEMBL11811303 0.67 TSHR (0.34) TSHRNLRP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024186176-A1 METHOD FOR PREPARING MODIFIED NUCLEOSIDES FROM THYMIDINE 주식회사 압타머사이언스 2024-09-12 WO claimed
US-20250059227-A1 ARTIFICIAL NUCLEIC ACID, METHOD FOR PRODUCING SAME, AND USE OF SAME RIKEN GENESIS CO., LTD. (JP) 2025-02-20 US disclosed
EP-4458836-A1 NOVEL ARTIFICIAL NUCLEIC ACID, METHOD FOR PRODUCING SAME, AND USE OF SAME Riken Genesis Co., Ltd. (JP) 2024-11-06 EP disclosed
WO-2024186176-A1 METHOD FOR PREPARING MODIFIED NUCLEOSIDES FROM THYMIDINE 주식회사 압타머사이언스 2024-09-12 WO disclosed
US-20230212178-A1 METHOD OF PRODUCING PHOTOREACTIVE NUCLEOTIDE ANALOG JAPAN ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY (JP) 2023-07-06 US disclosed
WO-2023127857-A1 NOVEL ARTIFICIAL NUCLEIC ACID, METHOD FOR PRODUCING SAME, AND USE OF SAME 株式会社理研ジェネシス 2023-07-06 WO disclosed
US-20230160849-A1 Engineered DNA for Molecular Electronics UNIVERSAL SEQUENCING TECHNOLOGY CORPORATION (US) 2023-05-25 US disclosed
EP-4108670-A1 BRIDGED NUCLEOSIDE AND NUCLEOTIDE USING SAME OSAKA UNIVERSITY (JP) 2022-12-28 EP disclosed
US-9221864-B2 Tricyclic nucleic acid analogs ISIS PHARMACEUTICALS, INC. (US) 2015-12-29 US disclosed
US-20150112055-A1 TRICYCLIC NUCLEIC ACID ANALOGS ISIS PHARMACEUTICALS, INC. (US) 2015-04-23 US disclosed
US-8846637-B2 Substituted 2′-amino and 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom ISIS PHARMACEUTICALS, INC. (US) 2014-09-30 US disclosed
US-8796437-B2 Tetrahydropyran nucleic acid analogs ISIS PHARMACEUTICALS, INC. (US) 2014-08-05 US disclosed
US-20130211064-A1 TETRAHYDROPYRAN NUCLEIC ACID ANALOGS ISIS PHARMACEUTICALS, INC. (US) 2013-08-15 US disclosed
US-8501805-B2 Substituted alpha-L-bicyclic nucleosides ISIS PHARMACEUTICALS, INC. (US) 2013-08-06 US disclosed
US-20130131147-A1 SUBSTITUTED 2'-AMINO AND 2'-THIO-BICYCLIC NUCLEOSIDES AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM ISIS PHARMACEUTICALS, INC. (US) 2013-05-23 US disclosed
US-8440803-B2 Tetrahydropyran nucleic acid analogs ISIS PHARMACEUTICALS, INC. (US) 2013-05-14 US disclosed
US-8278426-B2 Carbocyclic bicyclic nucleic acid analogs ISIS PHARMACEUTICALS, INC. (US) 2012-10-02 US disclosed
US-20120071645-A1 TETRAHYDROPYRAN NUCLEIC ACID ANALOGS ISIS PHARMACEUTICALS, INC. (US) 2012-03-22 US disclosed
US-20120021515-A1 OLIGOMERIC COMPOUNDS AND METHODS ISIS PHARMACEUTICALS, INC. 2012-01-26 US disclosed
US-20110166205-A1 SUBSTITUTED ALPHA-L-BICYCLIC NUCLEOSIDES IONIS PHARMACEUTICALS, INC. 2011-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230212178-A1 METHOD OF PRODUCING PHOTOREACTIVE NUCLEOTIDE ANALOG POLH, POLL, POLM TSHR 4018/4885NLRP3 3320/4885
US-20130131147-A1 SUBSTITUTED 2'-AMINO AND 2'-THIO-BICYCLIC NUCLEOSIDES AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM TYMS, NOP2, TYMP TSHR 3116/4885NLRP3 2997/4885
US-20120021515-A1 OLIGOMERIC COMPOUNDS AND METHODS HNRNPH1, RNASEH1, SNRPE TSHR 4204/4885NLRP3 2515/4885
US-20250059227-A1 ARTIFICIAL NUCLEIC ACID, METHOD FOR PRODUCING SAME, AND USE OF SAME NSUN3, NSUN2, LUC7L2 TSHR 1945/4885NLRP3 3407/4885
US-20150112055-A1 TRICYCLIC NUCLEIC ACID ANALOGS RRM2, RRM1, RNMT TSHR 2123/4885NLRP3 2626/4885
US-20120071645-A1 TETRAHYDROPYRAN NUCLEIC ACID ANALOGS HNRNPM, POLM, RNMT TSHR 3800/4885NLRP3 3693/4885
US-20110166205-A1 SUBSTITUTED ALPHA-L-BICYCLIC NUCLEOSIDES RNMT, HNRNPM, NSUN2 TSHR 4641/4885NLRP3 4221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.